Gastroesophageal Carcinogenesis
Research group
Group Leader
Manuel Ramón Pera Román
The sequential process prior to the appearance of a gastric or esophageal adenocarcinoma is a sequential histologically well-defined process characterized by the appearance of an intestinal phenotype. In the first stages of gastro-esophageal carcinogenesis the expression of intestinal markers, as intestinal transcription factors (CDX2), mucin genes (MUC2 and MUC4), intestinal enzymes and others, can be detected. We study the molecular mechanisms that can be initiating these processes, through the regulation of transcription factors inducing the acquisition of the intestinal phenotype. In the esophagus, the development of columnar metaplasia (Barrett’s esophagus) is a response to a chronic gastroesophageal reflux injury and is a major risk factor for esophageal adenocarcinoma. Patients undergoing esophagectomy with a gastric conduit reconstruction develop columnar metaplasia in the remnant esophagus on a background of significant reflux, providing a useful model to study the early molecular events in the development of Barrett’s esophagus. MiRNAs expression profiles may identify a characteristic signature that could distinguish between normal squamous epithelium, esophagitis, cardiac-type epithelium, and intestinal metaplasia. A group of miRNAs may selectively target specific transcriptional factors (CDX2) involved in the Barrett’s development.
Members
Mar Iglesias Coma (Researcher)
Marta Garrido Saldaña (Technician)
Main Publications
• Rice TW, Ishwaran H, Hofstetter WL, Schipper PH, Kesler KA, Law S, Lerut EM, Denlinger CE, Salo JA, Scott WJ, Watson TJ, Allen MS, Chen LQ, Rusch VW, Cerfolio RJ, Luketich JD, Duranceau A, Darling GE, Pera MR, Apperson-Hansen C, Blackstone EH. Esophageal Cancer: Associations With (pN+) Lymph Node Metastases. Ann Surg 2017; 265(1): 122-129. IF 8.98. D1.
• Goday A, Farré M, Rodríguez-Morató J, Ramón-Moros JM, Pérez-Mañá C, Papaseit E, Civit E, Langohr K, Carbó M, Benaiges D, Castañer O, Flores JA, Pera MR, Grande L, de la Torre R. Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism. Obes Surg 2017; 27(12): 3194-3201. IF 3.947. D1.
• Custodio A, Carmona-Bayonas A, Jiménez-Fonseca P, Sánchez ML, Viudez A, Hernández R, Cano JM, Echavarría I, Pericay C, Mangas M, Visa L, Buxo E, García T, Rodríguez Palomo, Álvarez Manceñido, Lacalle A, Macías I, Azkarate A, Ramchandani A, Fernández Montes, López C, Longo F, Sánchez Bayona, Limón ML, Díaz-Serrano A, Hurtado A, Madero R, Gómez C, Gallego J, and on behalf of the AGAMENON study group. Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. Br J Cancer 2017; 116(12): 1526-1535. IF 6.176. Q1.
• Jiménez Fonseca P, Carmona-Bayonas A, Hernández R, Custodio A, Cano JM, Lacalle A, Echavarría I, Macías I, Mangas M, Visa L, Buxo E, Álvarez-Manceñido F, Viudez A, Pericay C, Azkarate A, Ramchandani A, López C, Martínez de Castro E, Fernández-Montes A, Longo F, Sánchez-Bayona R, Limón ML, Díaz-Serrano A, Martín Carnicero A, Arias D, Cerdà P, Rivera F, Vieitez JM, Sánchez-Cánovas M, Garrido M, Gallego J. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. Br J Cancer 2017; 117(6): 775-782. IF 6.176. Q1.
• Jiménez-Fonseca P, Carmona-Bayonas A, Sánchez-Lorenzo ML, Gallego-Plazas J, Custodio A, Hernández R, Garrido M, García T, Echavarría I, Cano JM, Rodríguez-Palomo A, Mangas M, Macías I, Ramchandani A, Visa L, Viudez A, Buxó E, Díaz-Serrano A, López C, Azkarate A, Longo F, Castañón E, Sánchez-Bayona R, Pimentel P, Limon ML, Cerdà P, Álvarez-Llosa R, Serrano R, Lobera MP, Alsina M, Hurtado-Nuño A, Gómez-Martín C. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. Gastric Cancer 2017; 20(3): 465-474. IF 5.454. Q1.
• Climent M, Munarriz M, Blazeby JM, Dorcaratto D, Ramón-Moros JM, Carrera MJ, Fontané L, Grande L, Pera MR. Weight loss and quality of life in patients surviving 2 years after gastric cancer resection. Eur J Surg Oncol 2017; 43(7): 1337-1343. IF 3.522. Q1.
Ongoing Research Projects
• Regulación de CDX2 por miRNAs durante el proceso de intestinalización de la metaplasia cardial en un modelo humano de esófago de Barrett
- Fondo de Investigación Sanitaria. ISCIII (PI13/00989)
- From 2014 to 2017
- Principal investigator: Pera Román, Manuel Ramón
Group’s Recognitions
• Officially recognised as a consolidated research group by the Generalitat de Catalunya: Grup de Recerca en Carcinogènesi Gastroesofàgica i Inestabilitat Genòmica (2017-2019)
- Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR 51)
- Principal investigator: Pera Román, Manuel Ramón
Clinical Trials Signed in 2017
• Distribution of lymph node metastases in esophageal carcinoma [TIGER]
- Trial registration: NCT03222895
Theses
• Climent M. Resección con pretensión curativa del cáncer gástrico: Influencia de las complicaciones postoperatorias sobre la supervivencia y de la pérdida de peso sobre la calidad de vida. Autonomous University of Barcelona
- Director: Pera Román, Manuel Ramón; Grande L.
- Date of defense: 03/04/2017
• Salazar-Silva Y. Prótesis de rodilla dolorosa. Relación entre la analgesia endógena ineficiente y el dolor postquirúrgico persistente. Autonomous University of Barcelona
- Director: Pera Román, Manuel Ramón; Dürsteler C.
- Date of defense: 29/09/2017
Others
• Elected Society Director of the Executive Committee of the International Society for Diseases of the Esophagus (ISDE) (2017-2018).
• Elected member of the Scientific Committee of the Spanish Association of Surgeons
C/ Doctor Aiguader, 88
08003 Barcelona
(+34) 93 316 04 00
info@imim.es